secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001104659-24-037602
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics reports FY2023 net loss of $51.8M; BLA resubmission for cosibelimab targeted by mid-2024
--------------------------------------------------------------------------------

- Net loss $51.8M ($3.17 per share) vs $62.6M ($7.09) in FY2022; no revenue.
- Cash and equivalents $4.9M at Dec 31, 2023; Jan 2024 offering added $14.0M gross.
- R&D expenses $43.6M, down from $49.8M; G&A flat at $8.7M.
- CRL from FDA in Dec 2023 only cited CMO inspection issues; resubmission planned mid-2024.
- Appointed Dr. Amit Sharma to board; raised ~$47.6M via offerings in 2023-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/0001104659-24-037602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924037602/tm249333d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer